article thumbnail

STAT+: Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more

STAT

Hims & Hers Health plans to sell compounded versions of Novo Nordisk’s popular weight loss drug Wegovy to patients in certain professions for $99 a month , Reuters says. Compounded GLP-1 injections are fulfilled and shipped from Hims & Hers affiliated pharmacies and are regulated by the FDA.

article thumbnail

Injectable drug delivery market to value $1139.4b by 2029

European Pharmaceutical Review

percent compound annual growth rate (CAGR) between 2024 to 2029. billion by 2029. by 2029 appeared first on European Pharmaceutical Review. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4 Eli Lilly and Company and Sandoz.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Venus Remedies gets marketing approval for gemcitabine and docetaxel from Serbia

Express Pharma

billion by 2029 at a compounded annual growth rate (CAGR) of 8.2 The high prevalence of breast cancer, ovarian cancer, pancreatic cancer and cancers of the lung and intestine is a key driver of the global oncology market, which was valued at $286.04 billion in 2021 and is projected to reach $536.01 per cent from 2021 to 2030.

article thumbnail

Multiple sclerosis market to generate sales of $29.8 bn by 2030: GlobalData

Express Pharma

billion in 2030 at a compound annual growth rate (CARG) of 4.6 The market for multiple sclerosis (MS) disease-modifying therapies (DMT) is set to experience moderate growth across the seven major markets (7MM*) from $18.9 billion in 2020 to $29.8 per cent, forecasts GlobalData. bn by 2030: GlobalData appeared first on Express Pharma.

article thumbnail

Eisai joins the ADC golden rush

Pharmaceutical Technology

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

article thumbnail

Novo Nordisk blockbuster Ozempic boasts 23% sales surge in 2023

Pharmaceutical Technology

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

article thumbnail

Verona builds case for COPD drug ensifentrine as filing nears

pharmaphorum

He said ensifentrine will “change the treatment paradigm” for COPD by providing bronchodilation and anti-inflammatory properties in one compound. Shares in Verona popped on the news, rising more than 40% to approach $19.50 and drive the company’s market cap to almost $1.5